Systems and methods for effective delivery of monoclonal antibodies to neurological targets - Patents.com

By aligning microbubble sizes with vessel diameters in the blood-brain barrier, the system enhances ultrasound-induced BBB disruption for effective monoclonal antibody delivery, addressing size mismatches and tissue damage issues.

JP2024545177APending Publication Date: 2024-12-05INSIGHTEC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024534593
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-09
Filing Date
2022-12-08
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current ultrasound technologies for disrupting the blood-brain barrier (BBB) face challenges in efficiently delivering monoclonal antibodies due to mismatched microbubble sizes with blood vessel diameters, leading to incomplete disruption and potential tissue damage.

Method used

A system that determines the distribution of vessel diameters in the target area and uses microbubbles with a matching size distribution to enhance BBB disruption, utilizing ultrasound transducers and controllers to optimize acoustic energy and microbubble generation, detection, and delivery.

Benefits of technology

This approach ensures efficient BBB disruption, minimizing tissue damage by aligning microbubble sizes with vessel diameters, thereby improving monoclonal antibody delivery to brain tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545177000001_ABST
    Figure 2024545177000001_ABST
Patent Text Reader

Abstract

A system and method are provided for initializing an ultrasound procedure relative to a target region, the method including determining a distribution of vessel diameters of vasculature in the target region, the method also including providing microbubbles in the target region having a size distribution related to the distribution of vessel diameters.The present invention relates generally to ultrasound procedures, and more particularly to systems and methods for initializing an ultrasound procedure relative to a target region while avoiding damage to healthy tissue.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 287,909 (filed December 9, 2021), the entire disclosure of which is incorporated by reference herein.

[0002] FIELD OF THEINVENTION The present invention relates generally to ultrasound procedures, and more particularly to systems and methods for initializing an ultrasound procedure relative to a target region while avoiding damage to healthy tissue. [Background technology]

[0003] background Monoclonal antibodies (mABs) have been used against many tumors with increasing success, but with respect to brain tumors, the blood-brain barrier (BBB) ​​is of particular concern. The BBB prevents antibodies from entering the normal brain. This is attributed to the size of the mABs, which are generally in the range of 15 kDa. The tumor itself may partially disrupt the BBB, and some mABs may enter the tumor. However, the BBB remains intact, especially at the periphery of the tumor, where cancer cells may have already infiltrated into normal brain tissue and where mAb delivery may be most therapeutically beneficial.

[0004] Various approaches to reversible targeted BBB disruption have been clearly demonstrated in the past decades, including the use of focused ultrasound. The use of focused ultrasound has various benefits. For example, the disruption can be localized to the target area, the disruption can be performed through an intact skull, and the disruption can be transient and controlled without serious side effects. BBB disruption with ultrasound typically involves the administration of microbubbles so that they reach the target area. Mechanical vibrations of these microbubbles caused by ultrasound disrupt the BBB. However, intense vibrations can cause bleeding, and slight vibrations may not provide sufficient BBB disruption. Current technology can use acoustic feedback to monitor that the vibrations are within a safe and effective margin. However, there may be no guarantee that these vibrations represent bubble activity in the target area - they may be coming from somewhere in the brain.

[0005] There are other limitations when using microbubbles to disrupt the BBB. Microbubbles cannot enter blood vessels in the brain (whose diameters are smaller than those of the microbubbles); for example, typical microbubbles may have diameters on the order of microns, whereas microcapillaries at tumor sites may only be nanometers wide. This means that the applied ultrasound may not affect a significant proportion of the intact BBB at the tumor site. Conversely, treatments performed using microbubbles in the nanometer diameter range (also known as nanobubbles) may not be effective in causing BBB disruption when there are larger blood vessels in the target area. Thus, there is a need for an approach that efficiently introduces microbubbles throughout the vasculature of the BBB site to be disrupted using ultrasound procedures. Summary of the Invention [Means for solving the problem]

[0006] Abstract According to an embodiment of the present invention, the distribution of vascular diameters of the vasculature in a target area is determined, and microbubbles with a similar size distribution are introduced prior to or simultaneously with the therapeutic application of ultrasound. The similar size distribution ensures that the microbubbles penetrate a significant proportion of the vasculature, enhancing the efficiency of BBB disruption when ultrasound energy is applied. The vasculature can be characterized (e.g., to determine the distribution of vascular diameters) using atlases, contrast ultrasound, ultrasound super-resolution imaging, ultrasound localization microscopy, magnetic resonance imaging (MRI), computed tomography (CT), or other suitable modalities.

[0007] Thus, in a first aspect, the present invention relates to a system for initializing an ultrasound procedure for a target region. In various embodiments, the system includes an ultrasound transducer and a controller configured to determine a distribution of vessel diameters of the vasculature in the target region, and to provide in the target region microbubbles having a diameter size distribution related to the distribution of vessel diameters - for example, a bubble:vessel diameter ratio ranging from 1:2 to 1:30 (so that for a 30 μm vessel, the optimal bubble diameter is 1 to 15 μm). Typically, the diameter ratio is considered over a range of diameters corresponding, for example, to a histogram bin range. Within each such bin range, the relative populations (histogram heights) of bubbles and vessels are preferably significantly different, with microbubbles being much more numerous than the corresponding vessels. The population ratio of microbubbles sized to a particular vessel size (or size range) is preferably greater than 10 2 Moderately low, 10 9The average microbubble size of a histogram bin may be as high as 30 μm. Thus, if the average vessel size of a histogram bin is 30 μm, the average microbubble size of its corresponding histogram bin may be 2 μm. And while the patterns of vessels and microbubble histogram bins may be similar (or even identical), the heights of the corresponding bins are significantly different; that is, there are many more bubbles than vessels. In some embodiments, the bubble size distribution is expressed in terms of concentration. In some embodiments, the concentration is the concentration in the bubble mixture or the estimated concentration in the target tissue or the concentration in the patient's blood.

[0008] However, it should be understood that the relationship between bubbles and vessel diameter may be more complicated than a simple ratio. For example, the relationship may be polynomial, exponential, or may be experimentally determined. Alternatively or additionally, the microbubble size distribution may be a function of the type of microbubble. In some embodiments, a vessel volume distribution is generated by a controller and a bubble distribution is selected based on the volume information. Alternatively or additionally, only a few significant bins (e.g., 2-5 bins) from the vessel size distribution may be selected and other bins may be ignored. In some embodiments, the bubble distributions for each of the significant bins are equal or nearly equal. In some embodiments, the bubble distributions are expressed in terms of bubble volume (i.e., the total volume of bubbles within each size range).

[0009] In some embodiments, the vessel diameter distribution and the microbubble size distribution are histogram distributions with the same (or substantially the same) number of bins. For example, the vessel diameter distribution and the microbubble size distribution can be histogram distributions with substantially similar peak patterns, even if the absolute heights of the corresponding peaks differ. The microbubbles can be generated by application of ultrasound in the target area or by application as a suspension. Microbubbles in the submicron range can also be applied as phase-shifting nanodroplets.

[0010] In some embodiments, the target is the blood-brain barrier. The vessels can be cortical vessels ranging in diameter from 4 μm (capillaries) to less than 100 μm (arteries / veins). For example, the vessel diameter distribution can have a peak at approximately 50 μm. The vessel size range of the relevant vasculature can be established by imaging the target region, for example, using magnetic resonance imaging (MRI) or other suitable imaging modalities. Alternatively, once the target region is identified, an atlas can be used to determine the vessel diameter distribution.

[0011] In some embodiments, the controller is further configured to determine at least one parameter associated with the ultrasound transducers to control acoustic energy emitted by transducer elements such that the acoustic energy exceeds a threshold level, thereby inducing microbubble generation. The parameter associated with the ultrasound transducers may consist of or include a frequency, amplitude and / or phase associated with one or more of the ultrasound transducers.

[0012] In some embodiments, the system further includes means for detecting characteristics of microbubbles in the target area. The detection means may include or consist of the ultrasound transducer, an acoustic signal detection device, or a second ultrasound transducer. In some embodiments, the characteristics may be or include the presence, concentration, and / or amount, and / or behavior or response (e.g., cavitation) of the microbubbles. The controller may be further configured to determine at least one parameter associated with the ultrasound transducer based at least in part on the detected characteristics of the microbubbles.

[0013] As used herein, the terms "approximately" and "substantially" mean ±20%, and in some embodiments, ±5%. References throughout this specification to "one example", "one example", "one embodiment", or "one embodiment" mean that a particular feature, structure, or characteristic described in connection with that example is included in at least one example of the technology. Thus, the occurrences of the phrases "in one example", "in one example", "one embodiment", or "one embodiment" in various places throughout this specification do not necessarily all refer to the same example. Furthermore, the particular features, structures, practices, steps, or characteristics may be combined in any suitable manner in one or more examples of the technology. The headings provided herein are merely for convenience and are not intended to limit or interpret the scope or meaning of the claimed technology.

[0014] BRIEF DESCRIPTION OF THE DRAWINGS In the drawings, like reference characters generally refer to the same parts throughout the different aspects. Also, the drawings are not necessarily to scale, emphasis instead generally being placed on illustrating the principles of the invention. In the following description, various embodiments of the invention are described with reference to the following drawings, in which: [Brief description of the drawings]

[0015] [Figure 1] FIG. 1 illustrates a schematic of an exemplary ultrasound system in accordance with various embodiments of the present invention.

[0016] [Diagram 2] FIG. 2 shows an exemplary histogram of vessel size and microbubble size.

[0017] [Figure 3A] 3A-3C show a flowchart of an exemplary method for initializing an ultrasound procedure for a target region, according to some embodiments. [Figure 3B]3A-3C show a flowchart of an exemplary method for initializing an ultrasound procedure for a target region, according to some embodiments. [Figure 3C] 3A-3C show a flowchart of an exemplary method for initializing an ultrasound procedure for a target region, according to some embodiments. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] Detailed Description FIG. 1 illustrates an exemplary ultrasound system 100 for generating and delivering a focused acoustic energy beam to a target region 101 within a patient's body. The applied ultrasound waves may be reflected from the target region and / or non-target regions, and images of the target region and / or non-target regions may be generated based on the reflected waves. Additionally, microbubbles may be introduced into the target region 101 and / or non-target regions to increase ultrasound reflections, thereby improving contrast of the ultrasound image. In some embodiments, the applied ultrasound waves may ablate tissue in the target region 101 and / or induce microbubble vibration and / or cavitation to improve treatment effects. The illustrated system 100 includes a phased array 102 of transducer elements 104, a beamformer 106 that drives the phased array 102, a controller 108 in communication with the beamformer 106, and a frequency generator 110 that provides input electrical signals to the beamformer 106. In various embodiments, the system further includes an imager 112 (e.g., a magnetic resonance imaging (MRI) device, a computed tomography (CT) device, a positron emission tomography (PET) device, a single photon emission computed tomography (SPECT) device, or an ultrasound diagnostic device) for determining anatomical characteristics (e.g., type, characteristics, structure, thickness, density, etc.) of tissue in the target region 101 and / or non-target regions.

[0019] The array 102 may have a curved (e.g., spherical or parabolic) shape suitable for placement on the surface of a patient's body, or may include one or more flat or otherwise shaped cross sections. Its dimensions may vary between millimeters and tens of centimeters. The transducer elements 104 of the array 102 may be piezoelectric ceramic elements or may be mounted in silicone rubber or any other material suitable for damping the mechanical linkage between the elements 104. A piezo-composite material, or generally any material capable of converting electrical energy into acoustic energy, may also be used. To ensure maximum power transfer to the transducer elements 104, the elements 104 may be configured for electrical resonance at, for example, 50 Ω, to match (or substantially match) the input connector impedance.

[0020] The transducer array 102 is coupled to a beamformer 106 that drives the individual transducer elements 104 so that they collectively generate a focused ultrasound beam or field. For n transducer elements, the beamformer 106 may include n driver circuits, each including or consisting of an amplifier 118 and a phase delay circuit 120; each driver circuit drives one of the transducer elements 104. The beamformer 106 receives a radio frequency (RF) input signal, typically in the range of 0.1 MHz to 10 MHz, from a frequency generator 110, which may be, for example, a Model DS345 generator available from Stanford Research Systems. The input signal may be split into n channels for the n amplifiers 118 and delay circuits 120 of the beamformer 106. In some embodiments, the frequency generator 110 is integrated with the beamformer 106. The radio frequency generator 110 and the beamformer 106 are configured to drive the individual transducer elements 104 of the transducer array 102 at the same frequency but at different phases and / or different amplitudes.

[0021] The amplification or attenuation coefficients α1 to α n and phase shift a1~a n serves to transmit and focus the ultrasonic energy to the target region 101 through intervening tissue located between the transducer elements 104 and the target region, taking into account wave distortions induced in the intervening tissue. The amplification factor and phase shift are calculated using the controller 108, which may provide the computational functionality via software, hardware, firmware, hardwiring, or any combination thereof. In various embodiments, the controller 108 utilizes a general-purpose or special-purpose digital data processor programmed with software to determine optimal values ​​of the ultrasonic parameters (e.g., frequency, phase shift and / or amplification factor) associated with each element 104 to generate the desired focus or any other desired spatial field pattern in a conventional manner and without undue experimentation. The optimal values ​​of the ultrasonic parameters may be empirically refined one or more times before, after, and / or during the ultrasound procedure, based, for example, on the focusing quality, the focus position relative to the target 101 and / or the microbubble response to the ultrasonic treatment. The quality and position of the focusing can be monitored using an imager 112, and the microbubble response can be detected using a transducer 102 and / or an acoustic signal detector 122 (eg, a hydrophone).

[0022] In certain embodiments, optimal values ​​of ultrasound parameters are computationally estimated based on detailed information about the characteristics of the intervening tissues and their effects on the propagation of acoustic energy (e.g., reflection, refraction, and / or scattering). Such information may be obtained from the imager 112 and analyzed manually or computationally. Image acquisition may be three-dimensional, or alternatively the imager 112 may provide a set of two-dimensional images suitable for reconstructing a three-dimensional image of the target and / or non-target regions. Image manipulation functions may be implemented in the imager 112, in the controller 108, or in a separate device.

[0023] In a particular treatment scenario, ultrasound waves propagating from different directions towards the target region 101 may encounter highly variable anatomical structures (e.g., different thicknesses of tissue layers and different acoustic impedances); as a result, energy deposition in the target region 101 varies significantly, often non-monotonically with frequency, and the optimal frequency for a particular patient is typically unpredictable. Thus, in some embodiments, the frequency of the ultrasound is optimized by sequentially sonicating the target region 101 with waves having various "test frequencies" within a test frequency range; for each test frequency, a parameter indicative of energy deposition in the target region 101 (e.g., temperature, acoustic force, tissue displacement, etc.) is measured. The test range may span the entire range of frequencies suitable for ultrasound treatment (e.g., in various embodiments, 0.1 MHz to 10 MHz), but is typically a much smaller subrange thereof within which the optimal frequency is predicted. Such subranges may be determined, for example, based on computational estimates of optimal frequencies, results of simulations, or experimental data obtained for the same target in other patients. Further details regarding determining optimal frequencies for ultrasound applications are provided, for example, in U.S. Publication No. 2016 / 0008633, the entire contents of which are incorporated herein by reference.

[0024] In some embodiments, optimizing the ultrasound frequency involves iteratively setting test frequencies, sonicating the target region 101 at the selected frequencies, and quantitatively evaluating the resulting focusing characteristics or energy deposition in the target region 101. This may be accomplished using, for example, MRI thermometry to measure the temperature rise in the target region 101 resulting from the deposited energy, MR-ARFI to measure tissue displacement resulting from acoustic pressure in the target region 101, ultrasound detection to measure the intensity of ultrasound reflected from the target region 101, or generally any experimental technique to measure parameters that correlate in a known and predictable manner with energy deposition in the target region 101. After frequency optimization, the phase and / or amplitude settings of the phased array transducer 102 may be adjusted to optimize focusing for the selected frequencies. Approaches for assessing the focusing characteristics at a target region 101 and adjusting the ultrasonic frequency, phase and / or amplitude settings of a phased array transducer 102 based thereon are provided, for example, in International Patent Application entitled "Adaptive, Closed-Loop Ultrasound Therapy," filed on even date herewith, the entire contents of which are incorporated herein by reference.

[0025] In various embodiments, microbubbles and / or other therapeutic agents are introduced intravenously, or in some cases by injection proximal to the target region 101 using a delivery system 124 to enhance the ultrasound procedure on the target region. For example, microbubbles may be introduced into the patient's brain in the form of liquid droplets that subsequently evaporate, or as gas-filled bubbles, or entrained with another suitable substance, such as a conventional ultrasound contrast agent. Due to their gas encapsulation, microbubbles may act as scatterers / harmonic oscillators or reflectors of ultrasound. Reflections from microbubbles may be stronger than reflections from soft tissues and / or blood in the body. Thus, by using a microbubble-based contrast agent, the contrast level of ultrasound images may be significantly increased.

[0026] Furthermore, microbubbles may respond to the applied oscillating acoustic pressure with a volume pulsation. Depending on the ultrasound amplitude, the microbubble oscillations are either linearly or nonlinearly related to the applied acoustic pressure. For relatively low acoustic pressures, the instantaneous radius of the microbubble may oscillate linearly in relation to the amplitude of the applied acoustic pressure. The microbubble oscillations are governed by parameters such as resonant frequency, damping coefficient, and shell properties. Thus, when the frequency of the applied acoustic wave is equal to the microbubble resonant frequency, the microbubble may experience large forces and collapse. This may result in undesirable damage to non-target tissue if the microbubble is present therein.

[0027] To avoid this undesirable effect, in various embodiments, the resonant frequency of the microbubbles is selected to be substantially different (e.g., two times larger) than the selected optimal ultrasound frequency. Furthermore, the transducer elements 104 are actuated to transmit waves with low acoustic power (e.g., 5 W) during the treatment. In this way, the microbubbles in the non-targeted regions may not respond to the applied acoustic field (or have a limited response without cavitation) since the ultrasound waves reaching the non-targeted regions have a low acoustic intensity and their frequency is substantially different from the resonant frequency of the microbubbles. This ensures that the non-targeted tissue is not damaged (or at least the amount is very limited). In contrast, in the target region 101 where the ultrasound beam is focused, the acoustic intensity is substantially greater than that outside the target region and may be sufficient to vibrate and / or collapse the microbubbles. This may enhance energy absorption in the target region 101 for tissue ablation and / or cause destruction of blood vessels for targeted drug delivery.

[0028] In some embodiments, the delivery system 124 adjusts one or more characteristics of the microbubbles depending on the tissue type. In some embodiments, the delivery system 124 selects for a particular tissue, for example, a mixture of microbubbles having a size distribution similar (e.g., substantially similar) to the distribution of blood vessel sizes in the tissue. The microbubble mixture, sometimes referred to as TUBs (therapeutic ultrasound bubbles), thereby diffuses throughout the vasculature of the target area, which can result in disruption, for example, throughout the periphery of the tumor and in the small capillaries at the site of a microtumor. More generally, based on the tissue to be treated or treatment feedback, an optimal mixture of bubble types is used for treatment or for the continuation of treatment. The bubble types can be selected based on one or more of the following tissue parameters: (i) mechanical properties such as elasticity, (ii) resilience of the tissue to treatment, (iii) biological properties (e.g., affinity to bubbles), (iv) distribution of blood vessel diameters. Additionally, feedback received during treatment (e.g., MRI imaging to reveal acoustic response and / or tissue permeability) can suggest modifications to the bubble mixture composition. Relevant feedback parameters include (i) acoustic response (e.g., power spectrum of tissue response), (ii) MRI imaging (e.g., uniformity of contrast enhancement), and (iii) immediate or delayed physiological response. For example, if the physiological or acoustic response or uniformity of contrast enhancement is too low or too high, the microbubbles can be replaced with a mixture that exhibits a higher or lower response to acoustic energy.

[0029] In various embodiments, the bubble types may be distinguished from the following characteristics: (i) shell composition, (ii) gas composition, (iii) size, (iv) preparation procedure, and (v) "piggyback" substances (e.g., MRI contrast agents, targeting bodies). Microbubble preparations with different shell and gas compositions are commercially available and may be stored, for example, in different compartments of the administration system 124. In response to changes in the values ​​of the feedback parameters, the controller 108 may vary the mixture of bubbles delivered by the administration system 124 during the procedure. The same principle may be used to achieve a desired microbubble size distribution. As described in International Application No. PCT / IB2018 / 001537, filed December 5, 2018, the entire disclosure of which is incorporated herein by reference, a desired microbubble size distribution may be achieved by selective filtration and administration. Alternatively, the administration system 124 may have compartments containing commercially available microbubble preparations with different size distributions. These can be combined in various ratios by simultaneous or sequential application to achieve the desired size distribution. Furthermore, techniques such as decantation, centrifugation, and pore-filtration can be used to isolate microbubble sizes from natural commercially available contrast agents (see, for example, Cheung et al., "In vitro characterization of the subharmonic ultrasound signal from definity microbubble at high frequencies", Phys. Med. Biol. 53, 1209-1223(2008); Feshitan et al., "Microbubble size isolation by differential centrifugation", J. Colloid Interface Sci. 329, 316-324 (2009)).Additionally, the time evolution of microbubble size can be used to create contrast agents with a lower median size than the native agent, as described in Shekhar et al., "Modifying the size distribution of microbubble contrast agents for high-frequency subharmonic imaging," Med. Phys., Aug. 2013, 40(8): 082903. The aforementioned references are incorporated herein by reference in their entireties.

[0030] It should be emphasized that microbubbles represent one example of a treatment enhancer. Alternatively or additionally, nanodroplets or nanoparticles (e.g., gold seeds) may be used. Furthermore, the term "mixture" as used herein is generally understood to imply a combination of bubble types administered together. However, in some embodiments, the mixture includes various types of bubbles administered sequentially. Sometimes, the activity of one bubble type is a prerequisite for the success of another bubble type used simultaneously or subsequently. These and other aspects of the administration of microbubbles are further described below with reference to Figures 2 and 3A-3C.

[0031] 2 illustrates an exemplary binned distribution of vessel and microbubble sizes, according to some embodiments. Histogram 200 corresponds to the distribution of sizes (μm) (i.e., diameters) of blood vessels 204, and histogram 206 corresponds to the distribution of sizes (i.e., diameters) of microbubbles 210 generated based on the distribution illustrated in histogram 200. The y-axes 202 and 208 correspond to the frequency (or, in some cases, absolute number) of blood vessels and microbubbles, respectively, in each size bin. For ease of illustration, the histogram heights for blood vessels and microbubbles are shown as equal; however, as explained above, the heights of the microbubble histogram bins are much higher (e.g., 10 s) than those of the blood vessel histogram bins. 2 ~10 9 times). Moreover, these example values ​​are shown for illustrative purposes and should not be construed as limiting the selection of size values. In particular, the range of vessel sizes may vary for different tissues or for the same tissue but different patients. Similarly, the number of bins or buckets (five in the example shown) may vary for different tissues and / or different patients for each embodiment. The number of size bins suitable for a particular application is straightforward to determine without undue experimentation and typically depends most heavily on the width of the vessel size distribution and the degree of control that can be exerted over the microbubble size distribution. Since the objective is to enhance overall efficiency rather than precisely placing the same number of microbubbles in the vessels, the overall distribution pattern is more important than the number of bins. In some cases, as few as two bins may be sufficient, but a wider size distribution will require a larger number of bins (e.g., five as shown, or ten or more). It should be emphasized that in practice, the distribution patterns do not need to match exactly; in fact, errors in matching up to 50% can be tolerated.

[0032] Furthermore, the number of bins or buckets shown in histogram 206 need not match the number of bins in histogram 200. In other words, the mapping from one histogram to the other need not be one-to-one, and multiple buckets in one histogram 200, 206 may be mapped to the same bucket in the other histogram. In this way, different embodiments may be optimized for different situations, depending on factors such as tissue type, size, and location, feasible obtainable accuracy of the microbubble size distribution, etc. Some embodiments generate substantially similar distributions through the above mapping. Although the histogram profile shown in FIG. 2 generally follows a Gaussian distribution with a peak height, this need not be the case. Instead, the size distribution may be linear, flat, may decrease exponentially from a peak value, or may follow another pattern. However, the overall objective is still to align the distribution of microbubble sizes and the distribution of vessel sizes according to a predetermined relationship.

[0033] The relationship may be linear - for example, the ratio of microbubble diameter to corresponding vessel diameter ranges from 1:2 to 1:30; in the figures, to repeat and easily show, the ratio is approximately 1:2 across the bins. In other embodiments, the predetermined relationship is polynomial, exponential, or experimentally determined. To experimentally determine the relationship, mixtures with different narrow bubble distributions may be used in different experiments. In each experiment, the dominant vessel size in each region is compared to the aperture measured by a marker (e.g., gadolinium in MRI) and the best performing bubble mixture is determined, thereby revealing the optimal approximate microbubble diameter. Mixtures with similar size distributions but different concentrations may be used to establish optimal bubble-to-vessel ratios for optimal bubble sizes. To treat large regions with a wide distribution of vessel sizes, combinations of bubble mixtures may be used based on experimentally established size and concentration relationships for each vessel size.

[0034] Alternatively or additionally, the microbubble size distribution may be a function of the type of microbubble: shell type and gas type, for example, strongly affect how the acoustic field interacts with the bubbles.

[0035] Furthermore, the overall ratio of microbubbles to correspondingly sized blood vessels can be determined experimentally and adjusted for different applications, different antibodies or drugs, etc. An exemplary representative size range for microbubbles is 0.5-20 μm, with a peak of, for example, 1-5 μm.

[0036] 3A-3C show a flowchart of an exemplary method 300 for initializing an ultrasound procedure for a target region, according to some embodiments. The method (or process) may be performed in an electronic device having one or more processors and memory. The memory stores one or more programs configured for execution by the one or more processors. The method may be performed by a controller (e.g., controller 108), a dispensing system or dispensing device 124, a combination of components, or some or all of the components of the system 100 described above with reference to FIG. 1. The controller 108 or dispensing device 124 may be configured to perform any of the methods described herein, according to some embodiments.

[0037] As shown in FIG. 3A, method 300 includes determining a distribution of vessel diameters of vasculature in a target region (step 302). In some embodiments, the target includes a portion of the blood-brain barrier (step 306). For example, the vessels may be cortical vessels ranging in diameter from 4 μm to less than 100 μm (step 308). In some embodiments, the determining step includes imaging the target region (step 310), for example, using contrast MRI / Doppler ultrasound or MRI perfusion (in the latter case based on known correlations between perfusion rate and vessel size).

[0038] Referring now to FIG. 3B, in some embodiments, the determining step 302 includes identifying the target region (step 324) and determining the distribution of vessel diameters using an atlas (which may be a standard reference, e.g., Mouches et al., “A statistical atlas of cerebral arteries generated using multicenter MRA datasets from healthy subjects”, Scientific Data 6, Art. No. 29 (2019), which is incorporated herein by reference). Alternatively, vessel size may be characterized by MRI or other tomographic imaging techniques; sequential tomographic slices representative of the target tissue are analyzed and vessel diameter statistics are computationally determined. Next, at least one parameter associated with the ultrasound transducer is determined (step 326) to control the acoustic energy emitted by the transducer elements such that the acoustic energy exceeds a threshold level to induce microbubble generation and / or cavitation. In some embodiments, parameters associated with the ultrasonic transducer include frequency, amplitude and / or phase (step 328), which parameters typically vary between separately driven transducer elements of the ultrasonic transducer.

[0039] In other embodiments, contrast-enhanced ultrasound (CEUS) or ultrasound super-resolution imaging (e.g., using ultrasound localization microscopy or ULM) to generate vascular maps; see, e.g., PCT Publication No. WO 2021 / 123905 and Errico et al., "Ultrafast ultrasound localization microscopy for deep super-resolution vascular imaging," Nature, 527(7579), 499-502 (2015), the entire disclosures of which are incorporated herein by reference. In the case of CEUS, harmonic or time-varying echoes are known to originate from intravascular bubbles. After generating a spatial map of bubbles in each CEUS image frame, extraneous tissue-related noise is removed from the desired bubble signal in a process known as beamforming. CEUS processing involves denoising the beamformed bubble images over time to generate a sharp, low-resolution image of the vasculature. ULM processing involves finding the exact location of resolvable bubbles and collecting this information over a series of frames to generate a super-resolution image of the vasculature. High and / or low microbubble concentrations, long (ms) and / or short (μs) pulses, and long and / or short acquisitions may be used depending on the implementation.

[0040] Since microbubbles are purely intravascular, their possible locations can be constrained according to the super-resolution vascular map. The acoustic pulses used to disrupt the BBB are typically long, but short echoes can be generated to generate a super-resolution passive acoustic map by slightly modulating the transmitted frequency (ultrasound encoding) and isolating the desired frequencies at the receiving end. Forcing constraints such as sparsity and allowed reconstruction grids (according to the estimated super-resolution vascular map) on the passive acoustic mapping calculations can improve the reconstruction resolution beyond the diffraction limit, revealing details that are lost in conventional passive acoustic maps. These "priors" sparsity can be determined according to the bubble density in each vascular region (in a manner similar to that described in van Sloun et al., "Deep learning in ultrasound imaging", Proc. of IEEE, 108(1), 11-29 (2019)). The CEUS and ULM calculations may be aided by information from co-registered vascular maps acquired using various imaging modalities (eg, MM and CT).

[0041] CEUS and ULT can also be used to monitor treatment based on vascular changes (vasculature integrity, changes in vasculature diameter) by comparing vascular maps and flow rates and patterns during treatment with pre-treatment vasculature maps (or maps generated during the course of a pre-treatment session). In particular, tracking functional vasculature changes (e.g., functional vasculature density, diameter histogram, integrity, and flow patterns) can be used to infer treatment progress and update acoustic parameters for treatment. Sampling and comparison of vascular maps can occur between pulses, during multi-pulse sonication, and / or during treatment sessions. Tracked "feature" parameters characterizing changes in functional vasculature can be correlated with treatment progress based on traditional machine learning or other techniques (e.g., linear regression, random forest classification, neural networks, etc.). Classifiers are trained (or regression coefficients are predicted) based on feature parameter values ​​obtained during treatment and the actual progress of treatment, for example, as determined by MRI or CT monitoring and interpretation (which can be manual or automated). Feature parameter values ​​can be obtained in real time during the procedure from short scans and partial vascular information. Similarly, vascular reconstruction can be based on fitting expected bubble shapes (Errico et al., supra) or relying on the sparseness of the underlying vasculature (see, e.g., van Sloun et al., "Deep learning in ultrasound imaging," Proc. of IEEE, 108(1), 11-29 (2019)).

[0042] MRI and / or CT scans (e.g., CT-angiography) may be routinely acquired during treatment planning and may alternatively or additionally be used to characterize the vasculature. CT imaging may be performed using contrast agents.

[0043] 3A, the method also includes providing, in the target region, microbubbles having a size distribution related to the distribution of vessel diameters according to a predetermined relationship (step 312). In some embodiments, providing 312 includes generating the microbubbles by application of ultrasound in the target region. In other embodiments, providing 312 includes administering the microbubbles as a suspension.

[0044] 3C, in some embodiments, the method also includes detecting a characteristic of the microbubbles in the target region (step 330). The characteristic of the microbubbles may be detected using an ultrasound transducer, an acoustic signal detection device, or a second ultrasound transducer (step 332). In some embodiments, the characteristic is the presence, size distribution, concentration, and / or amount, and / or behavior or response (e.g., cavitation) of the microbubbles (step 334). In some embodiments, the method includes determining at least one parameter associated with the ultrasound transducer based at least in part on the detected characteristic of the microbubbles (step 336), e.g., varying the amplitude of various transducer elements to increase or decrease microbubble generation.

[0045] A representative end-to-end procedure using microbubbles with a target size distribution is as follows: Prior to and / or during an ultrasound procedure to treat a target tissue region (e.g., by applying sonication to ablate the target), a small population of transient microbubbles is provided to the target region to enable focusing at the target of the various ultrasound beams generated by the transducer elements that contribute to the treatment. The microbubbles may be generated using ultrasound pulses generated by the transducer elements themselves and / or may be introduced intravenously using the delivery system 124. The characteristics of the microbubbles (e.g., their presence, concentration and / or amount) and / or behavior or response (e.g., cavitation) are monitored using the acoustic signal detection device 122 and / or the transducer array 102 during the focusing process. This process is described, for example, in International Patent Application No. PCT / IB2017 / 000990 (filed July 19, 2017) and U.S. Patent Application No. 62 / 781,258 (filed December 18, 2018); approaches for delivering microbubbles to a target area are provided, for example, in the above-referenced '1537 PCT application; approaches for measuring microbubble characteristics and / or activity are provided, for example, in U.S. Patent Publication No. 2018 / 0206816 and International Application Nos. PCT / IB2018 / 000841 (filed June 29, 2018) and PCT / IB2018 / 000774 (filed May 22, 2018); and approaches for configuring a transducer array 102 to detect microbubble responses are provided, for example, in U.S. Patent Application No. 62 / 681,282 (filed June 6, 2018). The entire contents of these applications are incorporated herein by reference.

[0046] In one embodiment, after transducer parameters (e.g., frequency, phase shift and / or amplitude) that optimize focusing in the target region have been determined (e.g., via analysis of acoustic reflections from the microbubbles, as described above), the amount of microbubbles in the target region (and / or nearby non-target regions) is preferably limited to avoid undesired damage to non-target tissue during ablation of the target tissue. Thus, after the focusing procedure, the presence, amount and / or concentration of microbubbles in the target region (and / or nearby non-target regions) may again be measured based on acoustic signals transmitted or reflected from the microbubbles using the acoustic signal detection device 122 and / or the transducer array 102. If microbubbles are present (or in some embodiments, the amount exceeds a predetermined threshold that effectively eliminates clinically significant damage to the target and / or non-target tissue), a microbubble modulation approach may be implemented to eliminate (or at least reduce) microbubbles in one or more selected non-target regions that correspond to low sensitivity levels on the tissue sensitivity map; this may indirectly reduce the microbubble population in the target and / or nearby regions. The size distribution of the microbubbles is controlled as described above.

[0047] In various embodiments, the focused beam characteristics are optimized based on the characteristics of the microbubbles, including their ability to remove microbubbles. For example, the size and / or shape of the focus may be adjusted to match the size and / or shape of the microbubbles to be removed from the target area during the ultrasound procedure. In this way, the microbubble adjustment process may efficiently destroy selected microbubbles at a time. Alternatively, the focus may be shaped / sized to destroy only a portion of the microbubbles. For example, if some of the microbubbles are near an arterial wall, the cavitation may cause damage to the arterial wall; thus, the ultrasound controller 108 may shape and size the focus to destroy only a portion of the microbubbles that are not near the arterial wall. Adjustment of the focus size and / or shape may be accomplished by adjusting the amplification factor and / or phase shift of the ultrasound beam transmitted from the transducer elements as described above.

[0048] Although the primary force for distributing microbubbles into target regions and non-target regions outside the target is blood circulation, in some embodiments, the ultrasound transducer may be configured to create a focus that can induce the movement of microbubbles by applying acoustic radiation force thereto (e.g., by adjusting phase, amplitude, and / or frequency). For example, the generated focus may sweep at least some of the microbubbles from the target region (or regions with relatively high sensitivity scores) to regions of low sensitivity outside the target (e.g., facial veins). In one embodiment, the generated focus has a relatively low acoustic power sufficient to sweep the microbubbles without causing their cavitation.

[0049] In various embodiments, the focusing induces the movement of the microbubbles by applying an acoustic radiation force thereto. The acoustic radiation force is generated by changes in energy density and momentum of the propagating ultrasound waves resulting from absorption, scattering, or reflection from intervening tissues located between the transducer 102 and the target region. In general, the amplitude of the acoustic radiation force is proportional to the ultrasound intensity. Thus, in one implementation, the intensity of the ultrasound beam directed at the microbubbles is gradually increased until the acoustic radiation force generated is sufficient to manipulate and move the microbubbles. In another embodiment, prior to manipulation of the microbubbles, characteristics of the intervening tissue (e.g., absorption coefficient) are measured using the imager 112 as described above; the intensity of the ultrasound beam sufficient to move the microbubbles can be calculated based thereon. Once the microbubbles are moved away from the target region and / or reach a region with a relatively low sensitivity score, the controller 108 can increase the intensity of the ultrasound beam to cause microbubble cavitation in the region of low sensitivity. Here, since the cavitation occurs in the region of low sensitivity, any possible damage is clinically acceptable. Thus, this approach may advantageously allow for the removal of microbubbles from areas more vulnerable to ultrasound-induced microbubble cavitation (e.g., more sensitive areas) to areas less likely to be damaged by cavitation (e.g., less sensitive areas). As a result, unintended damage to healthy tissue in the target and / or non-target areas may be minimized.

[0050] It should be understood that the terms "point focus" and "line focus" as used herein do not refer to points and lines in the strict mathematical sense, but rather to focusing shapes that approximate a point or a line, respectively. Thus, the intensity distribution of a point focus (which may, for example, take the shape of a two-dimensional Gaussian distribution) may be characterized by a half-width in both dimensions of the focusing plane on the order of a few acoustic wavelengths, whereas the intensity distribution of a line focus (which may, for example, have a one-dimensional Gaussian profile perpendicular to the line) extends along the direction of the line but has a half-width perpendicular to the line on the order of only a few acoustic wavelengths.

[0051] In various embodiments, microbubble characteristics (e.g., quantity, concentration, size distribution, and / or response) during ultrasound-induced microbubble cavitation in selected regions of low sensitivity and / or during sweep from regions of relatively high sensitivity towards regions of relatively low sensitivity are monitored in real time using the acoustic signal detection device 122 and / or the transducer array 102, as described above.

[0052] In general, functionality for facilitating microbubble-mediated ultrasound focusing and treatment procedures and / or using microbubbles to enhance tissue effects such as reversible BBB opening may be built into one or more modules implemented in hardware, software, or a combination of both, whether integrated within the controller 108 and / or delivery system 124, or provided by a separate external controller or other computing entity or entities. Such functionality may include, for example, analyzing imaging data of the target and / or non-target regions acquired using imager 112, determining 3D voxel sets of the target and / or non-target tissues based on the imaging data, determining anatomical features associated with target / non-target tissues (e.g., vessel size distribution), having an acoustic signal detection device and / or transducer array detect acoustic signals transmitted or reflected from microbubbles, determining the amount, concentration, size distribution and / or response of microbubbles based on the detected acoustic signals, comparing the measured microbubble size distribution to a target size distribution and altering the detected size distribution to better match the target size distribution, configuring an ultrasound transducer array to generate a focal spot at the target tissue, adjusting ultrasound parameters, if necessary, to gradually clear excess microbubbles from the target region (or nearby non-target regions), and having an ultrasound transducer deliver ultrasound to the target region to initiate an ultrasound procedure (e.g., BBB opening to facilitate mAb administration), and / or monitoring microbubble response during an ultrasound procedure, as described above.

[0053] Additionally, the ultrasound controller 108 and / or controllers associated with the delivery system 124 and / or imager 112 may include one or more modules implemented in hardware, software, or a combination of both. For embodiments in which functionality is provided as one or more software programs, the programs may be written in any of a number of high-level languages, such as PYTHON, FORTRAN, PASCAL, JAVA, C, C++, C#, BASIC, various scripting languages, and / or HTML. Additionally, the software may be implemented in an assembly language directed to a microprocessor resident on a target computer; for example, the software may be implemented in Intel 80x86 assembly language if configured to run on an IBM PC or PC clone. The software may be embodied on an article of manufacture, including, but not limited to, a floppy disk, a jump drive, a hard disk, an optical disk, a magnetic tape, a PROM, an EPROM, an EEPROM, a field programmable gate array, or a CD-ROM. Embodiments using hardware circuitry may be implemented using, for example, one or more FPGA, CPLD, or ASIC processors.

[0054] The terms and expressions used herein are used as terms and expressions of description and not of limitation, and there is no intention in the use of such terms and expressions to exclude any equivalents of the features shown and described or portions thereof. Moreover, although certain embodiments of the invention have been described, it will be apparent to those skilled in the art that other embodiments incorporating the concepts disclosed herein may be used without departing from the spirit and scope of the invention. Thus, the described embodiments should be considered in all respects as illustrative only and not restrictive.

[0055] The following is claimed:

Claims

1. 1. A system for initiating an ultrasound procedure with respect to a target region, the system comprising: Ultrasonic transducer; and (a) determining a distribution of vessel diameters of the vasculature in a target region; and (b) providing microbubbles at the target area having a diameter size distribution that corresponds to the distribution of vessel diameters according to a predetermined relationship. A controller configured as follows: A system including:

2. The system of claim 1 , wherein the vessel diameter distribution and the microbubble size distribution are histogram distributions having approximately the same number of bins.

3. The bins of the histogram have heights that represent populations, and the microbubble population in a bin is 10 times the vessel population in the corresponding bin. 2 ~10 9 The system of claim 2 , wherein the

4. The system of claim 2 , wherein the vessel diameter distribution and the microbubble size distribution are histogram distributions having substantially corresponding peak patterns.

5. The system of claim 1 , wherein the predetermined relationship is a linear relationship.

6. The system of claim 5, wherein the linear relationship is a ratio of mean microbubble diameter to mean vessel diameter ranging from 1:3 to 1:

30.

7. The system of claim 1 , wherein the predetermined relationship is a polynomial relationship.

8. The system of claim 1 , wherein the predetermined relationship is an exponential relationship.

9. The system of claim 1 , wherein the predetermined relationship is empirical.

10. The system of claim 1 , wherein the distribution of vessel diameters is determined at least in part by contrast-enhanced ultrasound examination.

11. The system of claim 1 , wherein the distribution of vessel diameters is determined at least in part by ultrasound imaging.

12. The system of claim 11 , wherein the ultrasound imaging is super-resolution imaging.

13. The system of claim 1 , wherein the microbubble size distribution is a function of microbubble type.

14. The system of claim 1 , wherein the providing step comprises generating the microbubbles by application of ultrasound at the target area.

15. The system of claim 1 , wherein the providing step comprises dispensing the microbubbles as a suspension.

16. The system of claim 1 , wherein the target is the blood-brain barrier.

17. The system of claim 1 , wherein the vessels are cortical vessels ranging in diameter from 4 μm to less than 100 μm.

18. The system of claim 1 , wherein the distribution of vessel diameters has a peak at approximately 50 μm.

19. The system of claim 1 , wherein the determining step comprises imaging the target area.

20. The system of claim 1 , wherein the determining step comprises identifying the target region and determining a distribution of the vessel diameters using an atlas.

21. 10. The system of claim 9, wherein the controller is further configured to determine at least one parameter associated with the ultrasound transducer to control acoustic energy emitted by the transducer elements such that the acoustic energy exceeds a threshold level, thereby inducing microbubble generation.

22. 22. The system of claim 21, wherein the at least one parameter associated with the ultrasonic transducer includes at least one of a frequency, an amplitude, or a phase associated with at least one transducer element of the ultrasonic transducer.

23. The system of claim 1 , further comprising means for detecting a characteristic of the microbubbles in the target area.

24. 24. The system of claim 23, wherein the means for detecting a characteristic of the microbubbles comprises the ultrasound transducer, an acoustic signal detection device, or a second ultrasound transducer.

25. 24. The system of claim 23, wherein the characteristic is at least one of the presence, concentration and / or amount, and / or behavior or response (e.g., cavitation) of the microbubbles.

26. 24. The system of claim 23, wherein the controller is further configured to determine at least one parameter associated with the ultrasound transducer based at least in part on the detected characteristics of the microbubbles.

27. 1. A method of performing an ultrasound procedure, the method comprising: determining a distribution of vessel diameters of the vasculature in the target region; providing microbubbles at the target area having a diameter size distribution that corresponds to the distribution of vessel diameters according to a predetermined relationship; and applying ultrasonic energy to the target area in the presence of the microbubbles; The method includes:

Citation Information

Patent Citations

  • Three-dimensional radiation therapy accompanied by reduced stress of tissue and improved tolerable error of position

    JP2019048030A

  • Optimization of ultrasound frequency and microbubble size in microbubble-enhanced ultrasound treatment

    JP2020525168A

  • Controlling the delivery of therapeutic agents in microbubble-enhanced ultrasound procedures

    JP2021505289A

  • Controlling exogenous agent properties in microbubble-mediated ultrasound procedures

    JP2021505295A

  • Systems and methods for regulating microbubbles in ultrasound procedures

    WO2020208414A1